103 related articles for article (PubMed ID: 12583550)
1. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
Novelli A; Fallani S; Cassetta MI; Arrigucci S; Mazzei T
J Chemother; 2002 Dec; 14(6):584-90. PubMed ID: 12583550
[TBL] [Abstract][Full Text] [Related]
2. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.
Periti P; Mazzei T
J Chemother; 1999 Feb; 11(1):11-27. PubMed ID: 10078776
[TBL] [Abstract][Full Text] [Related]
3. Differential efficacy of clarithromycin in lung versus thigh infection models.
Maglio D; Capitano B; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
Chemotherapy; 2004 Jun; 50(2):63-6. PubMed ID: 15211079
[TBL] [Abstract][Full Text] [Related]
4. Effect of dosing intervals on efficacy of clarithromycin and erythromycin in mouse infection models.
Fernandes PB; Swanson RN; Hardy DJ; McDonald EJ; Ramer N
Drugs Exp Clin Res; 1988; 14(7):441-4. PubMed ID: 2977115
[TBL] [Abstract][Full Text] [Related]
5. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
Knudsen JD
Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary disposition of erythromycin, azithromycin, and clarithromycin in foals.
Suarez-Mier G; Giguère S; Lee EA
J Vet Pharmacol Ther; 2007 Apr; 30(2):109-15. PubMed ID: 17348895
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
Andes D; Craig WA
Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo.
den Hollander JG; Knudsen JD; Mouton JW; Fuursted K; Frimodt-Møller N; Verbrugh HA; Espersen F
Antimicrob Agents Chemother; 1998 Feb; 42(2):377-82. PubMed ID: 9527789
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.
Sun HK; Lee SY; Banevicius MA; Du X; Maglio D; Nicolau DP
J Antimicrob Chemother; 2005 Sep; 56(3):559-65. PubMed ID: 16024590
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin.
Gill CJ; Abruzzo GK; Flattery AM; Smith JG; Jackson J; Kong L; Wilkening R; Shankaran K; Kropp H; Bartizal K
J Antibiot (Tokyo); 1995 Oct; 48(10):1141-7. PubMed ID: 7490222
[TBL] [Abstract][Full Text] [Related]
12. Effect of erythromycin treatment delay on therapeutic outcome of experimental acute otitis media caused by Streptococcus pneumoniae.
Martínez-Marín C; Huelves L; del Prado G; García-Cía JI; Cenjor C; Ponte C; Granizo JJ; Soriano F
J Antimicrob Chemother; 2005 Oct; 56(4):783-6. PubMed ID: 16144869
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
Girard D; Finegan SM; Dunne MW; Lame ME
J Antimicrob Chemother; 2005 Aug; 56(2):365-71. PubMed ID: 16002421
[TBL] [Abstract][Full Text] [Related]
14. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.
Blondeau JM; Shebelski SD; Hesje CK
Int J Antimicrob Agents; 2015 Jun; 45(6):594-9. PubMed ID: 25752567
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2006 Jan; 50(1):243-9. PubMed ID: 16377693
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
Lepak AJ; Marchillo K; Craig WA; Andes DR
Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
[TBL] [Abstract][Full Text] [Related]
18. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia.
Lee PI; Wu MH; Huang LM; Chen JM; Lee CY
J Microbiol Immunol Infect; 2008 Feb; 41(1):54-61. PubMed ID: 18327427
[TBL] [Abstract][Full Text] [Related]
19. Penicillin pharmacodynamics in four experimental pneumococcal infection models.
Erlendsdottir H; Knudsen JD; Odenholt I; Cars O; Espersen F; Frimodt-Møller N; Fuursted K; Kristinsson KG; Gudmundsson S
Antimicrob Agents Chemother; 2001 Apr; 45(4):1078-85. PubMed ID: 11257018
[TBL] [Abstract][Full Text] [Related]
20. Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study.
Schentag JJ; Klugman KP; Yu VL; Adelman MH; Wilton GJ; Chiou CC; Patel M; Lavin B; Paladino JA
Int J Antimicrob Agents; 2007 Sep; 30(3):264-9. PubMed ID: 17587549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
